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Abstract 19 
With the aim to improve current therapeutic and monitoring options for 20 
diabetic cats, the present study compared pharmacodynamic parameters of 21 
protamine zinc insulin (PZI) and insulin degludec and validated the 22 
continuous glucose monitoring system (CGMS) iPro2 with Sof-sensor and 23 
Enlite-sensor focusing on the low glycemic range.  24 
Three doses (0.1, 0.2 and 0.3 IU/kg) of the two insulin preparations and the 25 
CGMS iPro2 with two different sensors were tested in six healthy cats. 26 
After each insulin administration, onset of action, time to glucose nadir and 27 
duration of action were calculated by measuring glucose concentrations 28 
with a portable blood glucose meter (PBGM). After sensor placement, 29 
paired PBGM and sensor glucose measurements were done and analytical 30 
and clinical accuracy were calculated according to the ISO 15197:2013 31 
criteria. 32 
Onset of action, time to glucose nadir and glucose nadir were similar for 33 
both insulin formulations. Duration of action of insulin degludec was 34 
significantly longer than those of PZI at 0.1 IU/kg (P = 0.043) and 0.2 IU/kg 35 
(P = 0.043). Overall, 166/191 (87%) Sof-sensor measurements and 106/121 36 
(88%) Enlite-sensor measurements met ISO criteria for analytical accuracy, 37 
and all sensor measurements fulfilled ISO criteria for clinical accuracy. 38 
Insulin degludec was well tolerated in healthy cats and showed longer 39 
duration of action than PZI. Further studies on the use of insulin degludec in 40 
diabetic cats might be recommended. Both sensors had good clinical 41 
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accuracy, when used with the CGMS iPro2, but the analytical accuracy was 42 
below the minimum set by ISO 15197:2013. 43 
44 
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1. Introduction 55 
Insulin is the cornerstone of treatment of cats with diabetes mellitus (DM). 56 
Duration of insulin action was reported to be the most important factor, that 57 
influences choice of insulin (Smith et al., 2012). A protamine zinc 58 
preparation (PZI) for use in cats recently became available on the European 59 
market. It is an intermediate to long-acting recombinant human insulin that 60 
has been shown to be effective in diabetic cats (Nelson et al., 2009; 61 
Norsworthy et al., 2009; Ward et al., 2015), but information about its 62 
pharmacodynamics in cats is scarce. Insulin degludec is a new ultra-long 63 
acting human insulin analogue. The formulation with a concentration of 100 64 
IU/mL is available on the market and could be used in diabetic cats. 65 
Compared with insulin glargine, insulin degludec has a predictable and 66 
stable glucose-lowering effect with fewer episodes of hypoglycemia in 67 
human patients with type 1 or type 2 DM (Birkeland et al., 2011; Heller et 68 
al., 2012; Rodbard et al., 2013). Moreover, when given three times a week, 69 
insulin degludec provides glycemic control comparable to once-daily 70 
treatment with insulin glargine (Zinman et al., 2011). To our knowledge, 71 
there are no reports of the glucose-lowering effects of insulin degludec in 72 
cats. 73 
The generation of glucose curves is commonly used by veterinarians to 74 
evaluate feline diabetic control (Smith et al., 2012). It helps in the 75 
identification of hypoglycemia, and supports the decisions on treatment 76 
adjustments. However, glucose curves have some limitations, even if the 77 
glucose measurements are obtained in the cat`s home environment. They do 78 
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not provide continuous information about blood glucose concentrations, or 79 
the glucose nadir and the glucose peak could be missed. In addition, the 80 
duration of action of the insulin cannot be determined if home monitoring is 81 
limited to a short period of time (i.e., <12 h). Another important limitation is 82 
that not all owners are able to collect blood from their cats and generate 83 
blood glucose curves. 84 
Real-time continuous glucose monitoring systems (CGMS) continuously 85 
measure the glucose concentration in the subcutaneous fat via a sensor 86 
containing glucose oxidase and immediately display recorded values on a 87 
monitor. These systems are considered useful for monitoring cats with DM 88 
(Ristic et al., 2005; Moretti et al., 2010; Dietiker-Moretti et al., 2011; Gough 89 
et. al., 2013; Hafner et al., 2013; Surman and Fleeman, 2013). However, 90 
CGMSs are not suitable for home-monitoring because the maximum 91 
distance between the cat and monitor should be only a few meters (Dietiker-92 
Moretti et al., 2011; Hafner et al., 2013). The CGMS iPro2 was designed to 93 
measure and record glucose values in humans for up to 7 days without 94 
displaying the data on a monitor; instead, at the end of the monitoring 95 
period, the data are uploaded on a computer and evaluated retrospectively. 96 
Because the iPro2 does not involve a monitor, it may be suitable for use in 97 
diabetic cats in their home environment. Two different sensor types are 98 
available, the enhanced Enlite-sensor and the Sof-sensor; the former is 99 
shorter, more flexible and more accurate than the latter (Siegmund et al., 100 
2011). In human patients, the Enlite-sensor tends to measure glucose levels 101 
lower than the reference over the entire glucose range, whereas the Sof-102 
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sensor measurements tend to be higher than reference values in the 103 
hypoglycemic range and lower than reference values in the hyperglycemic 104 
range (Calhoun et al., 2013). The use of the CGMS iPro2 and its reliability 105 
using these two sensors have not been described in cats. 106 
The aims of the study were to compare pharmacodynamic parameters of 107 
PZI and insulin degludec in cats, including onset of action, time to glucose 108 
nadir, glucose nadir and duration of action. Furthermore, ease of use, 109 
tolerability, side effects, reliability, and the accuracy of CGMS iPro2 using 110 
the two different sensors were evaluated. Particular attention was paid to the 111 
accuracy of the iPro2 in the low glycemic range, because reliability of 112 
measurements is crucial in hypoglycemic cats.113 
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2. Materials and Methods 114 
2.1 Animals 115 
Six healthy purpose-bred, neutered male, domestic shorthair cats were used. 116 
The median age was 3.7 years (range 3.4-3.7) and median body weight was 117 
5.0 kg (range 4.7-5.9). All cats had body condition score of 5 on a 9-poin 118 
scale. They were housed in groups of two, and were fed a commercial dry 119 
food for adult cats twice daily. Food intake was adjusted to maintain a stable 120 
body weight. During the 24 h before and after insulin administration, the 121 
cats were individually kept in cages routinely used for hospitalized animals. 122 
Food was withheld for 10 h before and 24 h after insulin injection. Cats had 123 
free access to water. The study protocol was approved by the veterinary 124 
office of the canton Zurich (permission number: 110/2014). 125 
 126 
2.2 Evaluation of two insulin preparations 127 
PZI 40 IU/mL (ProZinc, Boehringer Ingelheim, Basel, Switzerland) and 128 
insulin degludec 100 IU/mL (Tresiba, Novo Nordisk Pharma, Küsnacht ZH, 129 
Switzerland) were tested in a randomized crossover trial. Each cat received 130 
0.1, 0.2 and 0.3 IU/kg of PZI and insulin degludec SC, respectively, two 131 
weeks apart. Insulin syringes with 0.5 IU markings (Omnican 20, U-40 132 
insulin, BBraun, Melsungen, Germany; BD MicroFine 0.3 ml, U-100 133 
insulin, BD Medical, Le Pont de Claix, France) were used.  The dose was 134 
rounded up to the nearest half unit. Capillary blood glucose was measured at 135 
the inner pinna of an ear with a portable blood glucose meter (PBGM) 136 
AlphaTRAK2 (Abbott Animal Health, Baar, Switzerland) 30 and 5 minutes 137 
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before and 30, 60, 90, 120, 180, 240, 300 and 360 minutes after insulin 138 
injection and then every 2 h for another 18 h. Biochemical hypoglycemia 139 
was defined as blood glucose <3.6 mmol/L. 140 
If hypoglycemia caused vocalization, vomiting, tremors, or seizures, cats 141 
received canned food with glucose syrup (Jubin®, Andreas Jubin Pharma, 142 
Bochum, Germany), or 50% glucose solution (0.5-1 mL/kg) was infused 143 
intravenously. Hypoglycemia was not corrected, if only reduced physical 144 
activity was observed.  145 
Onset of insulin action, time to glucose nadir, and duration of insulin action 146 
were calculated as described by Clark et al. (2012). The onset of insulin 147 
action was defined as the interval between insulin administration and the 148 
first glucose concentration that was at least 2 standard deviations lower than 149 
baseline. The time to glucose nadir was defined as the interval between 150 
insulin administration and the lowest measured glucose concentration. The 151 
duration of insulin action was defined as the interval between the onset and 152 
the end of insulin action, when measured glucose concentrations had 153 
returned to within 2 standard deviations of baseline. The glucose data were 154 
withdrawn from the calculation, if the insulin tests were terminated 155 
(feeding, infusion of glucose solution), or if the onset of action could not be 156 
achieved. 157 
 158 
2.3 Technical features of the CGMS iPro2 and the two sensors 159 
The CGMS iPro2 (Medtronic, Münchenbuchsee, Switzerland) consists of a 160 
digital recorder (Fig.1a) and a disposable sensor. The Sof-sensor 161 
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(Medtronic, Münchenbuchsee, Switzerland) is 14.7 mm long and has a 162 
volume of 3.6 mm3 (Fig. 1b). It is inserted through the skin into the 163 
subcutaneous fat by means of a 17 mm 22 G needle at an angle of 45-60° 164 
and is fully hydrated within 10-15 minutes after positioning. The enhanced 165 
Enlite-sensor (Medtronic, Münchenbuchsee, Switzerland) is 9.6 mm long 166 
and has a volume of 0.2 mm3 (Fig.1c). It is inserted by means of a 10.5 mm 167 
27 G needle at a 90° angle and is fully hydrated within 5 minutes after 168 
positioning. Both sensors measure the interstitial glucose concentration in 169 
the subcutaneous fat via an electrode that contains glucose oxidase (Hafner 170 
et al., 2013). The iPro2 measures glucose concentrations between 2.2 and 22 171 
mmol/L every 5 minutes for up to 7 days. Data analysis is done using the 172 
CareLink iPro software (Medtronic, Münchenbuchsee, Switzerland).  173 
 174 
2.4 Evaluation of CGMS with two sensors 175 
The cats were alternately implanted with a Sof-sensor or an Enlite-sensor 24 176 
h before the insulin injection. The insertion and removal of the sensors were 177 
performed without sedation. Each sensor was placed in the subcutaneous 178 
tissue of the neck area on the right side and secured with cyanoacrylate 179 
adhesive (Cyanolit universal classic, 3M Consumer Healthcare, Rüschlikon, 180 
Switzerland) as described previously (Hafner et al., 2013). The recorder was 181 
connected to the sensor, initialized and then secured using a 3×7 cm piece of 182 
adhesive tape (Fig.1d). The video in the E-book chapter (Rand and Gottlieb, 183 
2017) contains detailed information about placement of the glucose sensor 184 
and iPro2-recorder. Calibrations were achieved by measuring capillary 185 
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blood glucose concentrations 1 and 3 h after insertion of the sensor and then 186 
every 8-12 h. Blood glucose concentrations were determined by use of the 187 
PBGM AlphaTRAK2 previously evaluated for use in diabetic cats 188 
(Cohenen et al., 2009; Zini et al., 2009). Each cat carried the sensor and the 189 
recorder on it for seven days. Thereafter, they were gently removed from the 190 
skin, and the glucose curve was downloaded. Ease of use of the sensors, 191 
tolerability, reliability of the measurements and side effects were recorded. 192 
 193 
2.5 Statistical analysis 194 
Results are reported as median and range or as percentage, as appropriate. 195 
Differences in pharmacodynamic parameters (onset of insulin action, time 196 
to glucose nadir, glucose nadir and duration of insulin action) between the 197 
same doses of two insulin preparations were analyzed using the Wilcoxon 198 
matched pairs signet rank test. The Friedman test was used to compare three 199 
different doses of one insulin formulation. Analytical and clinical accuracy 200 
of the sensors was calculated conforming to the international organization 201 
for standardization (ISO) 15197:2013 using Bland and Altman diagrams 202 
and consensus error grid coordinates, respectively (Bland and Altman, 203 
1986; Clarke et al., 1987). Accordingly, to be considered accurate, at least 204 
95% of glucose readings had to fall within ± 0.83 mmol/L of those 205 
measured with the reference method for concentrations <5.5 mmol/L or 206 
within ± 15% for concentrations ≥5.5 mmol/L, and at least 99% of readings 207 
had to be in zones A and B of the consensus error grid. To address the 208 
clinical importance of hypoglycemia, glucose curves with concentrations 209 
12 
 
predominantly <3.6 mmol/L were chosen for analysis. Paired glucose 210 
readings from the PBGM and the two sensors were divided into a group 211 
with PBGM readings <5.5 mmol/L and a group with PBGM readings ≥5.5 212 
mmol/L. Additionally, Spearman correlation coefficients (rho) were 213 
calculated for paired glucose readings. Differences were considered 214 
significant at P<0.05. A commercial software (GraphPad PRISM 6, 215 
GraphPad Software, La Jolla, USA) was used for analysis. 216 
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3. Results 217 
3.1 Evaluation of PZI and insulin degludec 218 
Protamine zinc insulin and insulin degludec were well tolerated by all cats 219 
and there were no injection site reactions. If the glucose lowering effect 220 
could be achieved, all three doses of both insulin formulations caused 221 
transient mild weakness, that was associated with biochemical 222 
hypoglycemia and resolved without treatment within 1-3 h in all cats. The 223 
onset of insulin action could not be achieved in three different cats treated 224 
with 0.1 IU/kg of PZI (one cat), 0.1 IU/kg of insulin degludec (one cat), and 225 
0.2 IU/kg of PZI (one cat). At the highest dose (0.3 IU/kg), PZI caused 226 
hypoglycemia, and vomiting in 3/6 (50%) cats; one of these cats had the 227 
same reaction after 0.3 IU/kg of insulin degludec. The hypoglycemia was 228 
corrected by feeding in three cats, and the glucose data were withdrawn 229 
from the calculation. One cat treated with 0.3 IU/kg of PZI quickly 230 
recovered without any interventions.  231 
Medians and ranges of pharmacodynamic parameters of both insulin 232 
formulations are shown in Table 1. Blood glucose curves are presented in 233 
Fig. 2 (a-f). Equal doses of PZI and insulin degludec did not differ with 234 
respect to glucose nadir, onset of action, and time to glucose nadir. Median 235 
duration of action was significantly shorter for 0.1 IU/kg of PZI (7 h; range 236 
1.5-7) than for 0.1 IU/kg of insulin degludec (11 h; range 9-22.5) (P=0.043) 237 
and for 0.2 IU/kg of PZI (6.8 h; range 4.5-10.5) than for 0.2 IU/kg of insulin 238 
degludec (12.5 h; range 8.0-20.0) (P=0.043). However, there were no 239 
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significant differences in the duration of action between two insulin 240 
formulations at 0.3 IU/kg. 241 
The duration of action of PZI never reached 12 h, while that of insulin 242 
degludec was ≥12 h in two cats with 0.1 IU/kg and in three cats with 0.2 and 243 
0.3 IU/kg (data not shown). Glucose nadir, onset of insulin action, time to 244 
glucose nadir, and duration of insulin action of PZI and insulin degludec 245 
were similar between different doses of each insulin formulations.  246 
 247 
3.2 Evaluation of CGMS with the Sof-sensor and Enlite-sensor 248 
The use of a total of 36 sensors (18 Sof and 18 Enlite) was scheduled. 249 
However, we used 48 sensors (24 Sof and 24 Enlite), because some sensors 250 
had to be replaced. Twenty of twenty-four (83%) Sof-sensors and 17/24 251 
(71%) Enlite-sensors were properly placed and initialized. The remaining 11 252 
sensors failed because of faulty manufacturing (1 Sof and 2 Enlite) or lack 253 
of initialization (3 Sof and 4 Enlite). One Enlite-sensor was bent during 254 
insertion. Both sensor types were easy to place and well tolerated by all 255 
cats. Abnormal behavior related to the sensors did not occur. All cats had 256 
mild local erythema after sensor removal, which resolved spontaneously 257 
within 12-24 h. One cat had a small dry scratch wound in the skin at the 258 
caudal border of the Sof-sensor and another cat had a similar wound at the 259 
caudal border of the Enlite-sensor. Both healed without treatment within 7-260 
10 days after sensor removal. 261 
Glucose concentrations were recorded by all 20 properly placed and 262 
initialized Sof-sensors and by 13/17 (76%) Enlite-sensors. Four (24%) 263 
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Enlite-sensors failed to record glucose concentration, because the recorder 264 
malfunctioned (two cats), the cat removed the sensor 1 h after insertion or 265 
for unknown reasons (one cat). Seventeen of the twenty (85%) functioning 266 
Sof-sensors and 6/13 (46%) functioning Enlite-sensors recorded the glucose 267 
concentration during the entire 7-day study period. The remaining 3/20 268 
(15%) functioning Sof-sensors and 3/13 (23%) Enlite-sensors recorded 269 
glucose concentrations during at least 50% of the study period. The four 270 
(31%) other functioning Enlite-sensors recorded glucose concentration 271 
during <50% of the study period. 272 
Uninterrupted recording of glucose concentrations occurred in 8/20 (40%) 273 
functioning Sof-sensors and in 8/13 (66%) functioning Enlite-sensors. 274 
Overall, there were 27 and 23 interruptions with the Sof-sensor and the 275 
Enlite-sensor, respectively. Twenty-three of the twenty-seven (85%) 276 
interruptions that occurred with the Sof-sensor and 16/23 (70%) that 277 
occurred with the Enlite-sensor lasted <1 h. The remaining four (15%) 278 
interruptions with the Sof-sensor and seven (30%) with the Enlite-sensor 279 
lasted between 1 and 24 h. 280 
A total of 191 paired PBGM-Sof-sensor and 121 paired PBGM-Enlite-281 
sensor glucose measurements were analyzed. One hundred and seventy-282 
seven of one hundred and ninety-one (93%) Sof-sensor measurements and 283 
113/121 (93%) Enlite-sensor measurements were between 2.2 and 5.5 284 
mmol/L. The remaining measurements were equal to 5.5 mmol/L or in the 285 
range between 5.5 and 22 mmol/L. The differences between glucose 286 
measurements from the PBGM and the two CGMS iPro2 sensors are shown 287 
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in Fig. 3. Considering the paired glucose measurements <5.5 mmol/L, 288 
160/177 (90%) Sof-sensor measurements and 102/113 (90%) Enlite-sensor 289 
measurements were within ± 0.83 mmol/L of the reference method and met 290 
the ISO accuracy criteria. Of the paired glucose readings ≥5.5 mmol/L, 6/14 291 
(43%) of Sof-sensor measurements and 4/8 (50%) Enlite-sensor 292 
measurements were within ± 15% of the reference method and met the ISO 293 
accuracy criteria. Overall, 166/191 (87%) Sof-sensor measurements and 294 
106/121 (88%) Enlite-sensor measurements met the ISO criteria for 295 
analytical accuracy. All glucose concentrations measured with both sensors 296 
were in zone A or B of the consensus error grid coordinates and met the ISO 297 
criteria for clinical accuracy (Fig. 4). There were moderate positive 298 
correlations between paired measurements from the PBGM and the Sof-299 
sensor (rho=0.67, P<0.0001) and between paired measurements from the 300 
PBGM and the Enlite-sensor (rho=0.69, P<0.0001). 301 
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4. Discussion 302 
This study compared pharmacodynamics of PZI and insulin degludec in 303 
healthy cats. Marked biochemical hypoglycemia and weakness occurred 304 
with both insulin formulations in all tests, when the glucose lowering effect 305 
was achieved. Vomiting was limited to three cats receiving the highest dose 306 
of PZI and to one cat receiving the highest dose of insulin degludec.  307 
Both types of insulin had a similar onset of action, time to glucose nadir and 308 
glucose nadir. Median duration of action was significantly longer for insulin 309 
degludec than for PZI at 0.1 and 0.2 IU/kg. The differences between two 310 
insulins at 0.3 IU/kg was not significant. However, the duration of action 311 
was about 1.5 times as long for insulin degludec than for PZI at all dose 312 
levels. The duration of action of PZI was shorter than 12 h in all cats 313 
irrespective of the doses. This differed from results of a recent study, in 314 
which PZI had a duration of action exceeding 12 h in some of the treated 315 
diabetic cats, and was therefore considered potentially useful for once-a-day 316 
treatment (Ward and Louviere, 2015). Longer duration of action of PZI in 317 
the mentioned study could be explained by the applied insulin dose (0.5 318 
IU/kg or higher). In our study, higher insulin dose was not associated with 319 
longer duration of action most likely due to rebound effect from 320 
hypoglycemia. In contrast to PZI, duration of action of insulin degludec was 321 
≥12 h in the most cats irrespective of the doses. These preliminary data 322 
justify a study on the use of insulin degludec as once-a-day treatment in 323 
diabetic cats. 324 
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Another objective of this study was to evaluate the CGSM iPro2 with the 325 
Sof-sensor and the Enlite-sensor. From a technical standpoint, the process of 326 
initialization of the iPro2, its calibration, and the range of glucose 327 
concentrations measured were similar to the real-time CGMS previously 328 
validated by our group (Moretti et al., 2009; Moretti et al., 2010; Hafner et 329 
al., 2013). Sensor insertion was straightforward, and the implanted sensor 330 
did not adversely affect cat's well-being. A unique feature of the CGSM 331 
iPro2 is that it allows for continuous glucose monitoring in cats in a home 332 
setting, which is a considerable advantage over the currently used real-time 333 
CGMSs that require the presence of a digital recorder in close proximity to 334 
the sensor. Therefore, the use of iPro2 might be recommended for cats with 335 
poor controlled DM, or if stress-induced hyperglycemia, rebound 336 
hyperglycemia, or large glycemic variability are suspected. 337 
The Sof-sensor was more reliable with regard to the initial glucose readings; 338 
all 20 placed Sof-sensors but only 13/17 Enlite-sensors successfully 339 
initiated glucose measurements after placement. Moreover, 17/20 Sof-340 
sensors but only 6/13 Enlite-sensors recorded glucose data during the entire 341 
7-day study period. Of note, 4/13 Enlite-sensors recorded glucose data 342 
<50% of the study period. Despite the overall superior performance of the 343 
Sof-sensor, the Enlite-sensors had numerically fewer interruptions of <1 h 344 
in glucose recording than the Sof-sensors; however, we considered 345 
occasional short interruptions in glucose recording of minor importance 346 
from a clinical standpoint, because they do not affect the interpretation of 347 
glucose curves in a significant way. Interruptions in glucose measurements 348 
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may occur with either sensor if they are not properly hydrated or regularly 349 
calibrated. Even slight changes in the position of the sensor caused by strain 350 
on the recorder or the overlying skin can temporarily interrupt 351 
measurements. The Enlite-sensor is thinner and shorter than the Sof-sensor 352 
and therefore might be more susceptible to interruptions. Taken together, 353 
our results suggest that the Sof-sensor is better suited to generate glucose 354 
curves in cats than the Enlite-sensor. 355 
Both sensors yielded similar and relatively good analytical accuracy based 356 
on correlation analysis but did not completely fulfil the ISO criteria. In fact, 357 
at glucose concentrations <5.5 mmol/L, both sensors had an analytical 358 
accuracy of 90%, which is below the required 95%, and at glucose 359 
concentrations ≥5.5 mmol/L, the analytical accuracy of the Sof-sensor and 360 
Enlite-sensor was 43% and 50%, respectively, both considerably lower than 361 
the required 95% accuracy. However, the present study involved healthy 362 
cats and focused on hypoglycemia and thus the number of glucose readings 363 
≥5.5 mmol/L was low. Including diabetic cats in future studies will aid in 364 
evaluation of the analytical accuracy of these sensors for glucose readings 365 
≥5.5 mmol/L.  366 
Clinical accuracy was evaluated by error grid analysis and was 100% for 367 
both sensors in the hypo- and normoglycemic ranges. According to ISO 368 
criteria, good clinical accuracy is achieved when at least 99% of glucose 369 
measurements fall within zones A and B of the consensus error grid 370 
coordinates, which occurred with both sensors in all cats. 371 
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The study has some limitations. First, it was performed in a small number of 372 
healthy young cats, and it might not reflect the effect of tested insulin 373 
formulations in older diabetic cats. Sensor glucose readings are affected by 374 
the hydration status of the subcutaneous fat, and it might be possible, that 375 
the reliability and accuracy of the Sof-sensor and the Enlite-sensor are 376 
adversely affected in older diabetic cats with compromised hydration. 377 
Second, the method used in the study to assess pharmacodynamic 378 
parameters of two insulin formulations is inferior to a isoglycemic clump 379 
method, which has been considered as a gold standard for the study of 380 
pharmacodynamics of insulin in people (Heise and Pieber, 2007; Gilor et 381 
al., 2010). Traditional blood glucose curves display the effects of exogenous 382 
insulin, endogenous insulin, glucagon, and stress hormones. Following 383 
severe hypoglycemia, a return of glucose to baseline reflects not only the 384 
diminishing effect of exogenous insulin, but could also be the result of 385 
activation of glucagon and stress hormones. In few cases (both insulin 386 
formulations, data not shown), we recognized a return of glucose 387 
concentration to baseline followed by another decline to a smaller degree as 388 
before. These could represent counter-regulatory response that masks the 389 
effect of exogenous insulin. However, it could also represent physiological 390 
glucose fluctuations. It is possible, that pharmacodynamic parameters of 391 
both insulin formulations were underestimated due to activation of glucagon 392 
and stress hormones. However, we assume, that the counter-regulatory 393 
response in cats was similar with both insulin formulations, and 394 
pharmacodynamic parameters could be easily compared. Third, we used 395 
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insulin syringes to inject small amounts of insulin (0.5 – 1.5 IU). Insulin 396 
syringes are known to be inaccurate and imprecise at doses lower than 5 IU 397 
(Keith et al., 2004). 398 
Fourth, the blood glucose was measured with PBGM and not with a routine 399 
chemistry analyzer. However, the PBGM AlphaTRAK is specially designed 400 
for use in pets. It was evaluated by different research groups, and was 401 
shown to be precise and accurate at low, normal and high glucose levels; 402 
glucose concentrations measured by AlphaTRAK did not significantly 403 
deviate from the reference method (Cohen et al., 2009; Zini et al., 2009).  404 
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5. Conclusions 405 
Pritamine zinc insulin and insulin degludec are well tolerated by healthy 406 
cats and cause similar degrees of hypoglycemia. Insulin degludec showed 407 
longer duration of action than PZI. Further studies on the use of insulin 408 
degludec in diabetic cats might be recommended. The CGMS iPro2 with the 409 
Sof-sensor or the Enlite-sensor is well tolerated by healthy cats. Both 410 
sensors provide good clinical accuracy but analytical accuracy does not 411 
reach the minimum set by ISO 15197:2013. The Sof-sensor seems more 412 
suitable for use in cats than the Enlite-sensor, because it produces initial 413 
glucose readings more reliably and has a better potential to generate glucose 414 
curves. However, pharmacodynamics of insulin degludec, and CGMS iPro2 415 
need to be investigated in a larger population of diabetic cats.  416 
 417 
Funding 418 
This research did not receive any specific grant from funding agencies in the 419 
public, commercial, or not-for-profit sectors. 420 
 421 
Conflict of interest 422 
Claudia Reusch has a consultancy agreement with Boehringer Ingelheim 423 
Vetmedica GmbH. 424 
23 
 
References 425 
1. Birkeland, K.I., Home, P.D., Wendisch, U., Ratner, R.E., Johansen, 426 
T., Endahl, L.A., Lyby, K., Jendle, J.H., Roberts, A.P., DeVries, 427 
J.H., Meneghini, L.F., 2011. Insulin degludec in type 1 diabetes: a 428 
randomized controlled trial of a new-generation ultra-long-acting 429 
insulin compared with insulin glargine. Diabetes care. 34, 661-665. 430 
2. Bland, J.M., Altman, D.G., 1986. Statistical methods for assessing 431 
agreement between two methods of clinical measurement. Lancet. 1, 432 
307-310. 433 
3. Calhoun, P., Lum, J., Beck, R.W., Kollman, C., 2013. Performance 434 
comparison of the Medtronic Sof-sensor and Enlite glucose sensors 435 
in inpatient studies of individuals with type 1 diabetes. Diabetes 436 
Technol Ther. 15(9), 758-761. 437 
4. Clark, M., Thomaseth, K., Heit, M., Hoenig, M., 2012. 438 
Pharmacokinetics and pharmacodynamics of protamine zinc 439 
recombinant human insulin in healthy dogs. J Vet Pharmacol Ther. 440 
35, 342-250. 441 
5. Clarke, W.L., Cox, D., Gonder-Frederick, L.A., Carter, W., Pohl, 442 
S.L., 1987. Evaluating clinical accuracy of systems for self-443 
monitoring of blood glucose. Diabetes care. 10, 622-628. 444 
6. Cohen T.A., Nelson R.W., Kass P.H., Christopher M.M., Feldman 445 
E.C., 2009. Evaluation of six portable blood glucose meters for 446 
measuring blood glucose concentration in dogs. JAVMA. 235(3), 447 
276-280. 448 
24 
 
7. Dietiker-Moretti, S., Muller, C., Sieber-Ruckstuhl, N., Tschour, F., 449 
Osto, M., Franchini, M., Ackermann, M., Lutz, T.A., Reusch, C.E., 450 
Zini, E., 2011. Comparison of a continuous glucose monitoring 451 
system with a portable blood glucose meter to determine insulin 452 
dose in cats with diabetes mellitus. J Vet Intern Med. 25, 1084-1088. 453 
8. Gilor, C., Ridge, T.K., Attermeier, K.J., Graves, T.K., 2010. 454 
Pharmacodynamics of insulin detemir and insulin glargine assessed 455 
by an isoglycemic clamp method in healthy cats. J Vet Intern Med. 456 
24, 870-874. 457 
9. Gough, S.C., Bhargava, A., Jain, R., Mersebach, H., Rasmussen, S., 458 
Bergenstal, R.M., 2013. Low-volume insulin degludec 200 units/mL 459 
once daily improves glycemic control similar to insulin glargine 460 
with a low risk of hypoglycemia in insulin-naive patients with type 2 461 
diabetes. Diabetes care. 36(9), 2536-2542. 462 
10. Hafner, M., Lutz, T.A., Reusch, C.E., Zini, E., 2013. Evaluation of 463 
sensor sites for continuous glucose monitoring in cats with diabetes 464 
mellitus. J Feline Med Surg. 15, 117-123. 465 
11. Heise, T., Pieber T.R., 2007. Towards peakless, reproducible and 466 
long-acting insulins. An assessment of the basal analogues based on 467 
isoglycemic clump studies. Diabetes Obes Metab. 9, 648-659 468 
12. Heller, S., Buse, J., Fisher, M., Garg, S., Marre, M., Merker, L., 469 
Renard, E., Russel-Jones, D., Philotheou, A., Francisco, A.M., Pei, 470 
H., Bode, B., BEGIN Basal-Bolus Type 1 trial investigators, 2012. 471 
Insulin degludec, an ultra-longacting basal insulin, versus insulin 472 
25 
 
glargine in basal-bolus treatment with mealtime insulin aspart in 473 
type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, 474 
randomised, open-label, treat-to-target non-inferiority trial. Lancet. 475 
379, 1489-1497. 476 
13. Keith, K., Nicholson, D., Rogers, D., 2004. Accuracy and precision 477 
of low-dose insulin administration using syringes, pen injectors and 478 
a pump. Clin Pediatr. 43(1), 69-74. 479 
14. Moretti, S., Tschuor, F., Osto, M., Franchini, M., Ackermann, M., 480 
Lutz, T.A., Reusch, C.E., Zini, E., 2010. Evaluation of a novel real-481 
time continuous glucose-monitoring system for use in cats. J Vet 482 
Intern Med. 24, 120-126. 483 
15. Moretti, S., Zini, E., Tschuor, F., Reusch, C.E., 2009. First 484 
experiences with the continuous real-time glucose monitoring 485 
system (Guardian REAL-time CGMS) in a cat with Diabetes 486 
mellitus. Schweiz Arch Tierheilkd. 151, 27-30. 487 
16. Nelson, R.W., Henley, K., Cole, C., Pzir clinical study group, 2009. 488 
Field safety and efficacy of protamine zinc recombinant human 489 
insulin for treatment of diabetes mellitus in cats. J Vet Intern Med. 490 
23, 787-793. 491 
17. Norsworthy, G., Lynn, R., Cole, C., 2009. Preliminary study of 492 
protamine zinc recombinant insulin for the treatment of diabetes 493 
mellitus in cats. Vet Ther. 10, 24-28. 494 
26 
 
18. Rand, J. and Gottlieb S.A., 2017. Feline diabetes mellitus, in: 495 
Ettinger, S.T., Feldman E.C., Cote, E. (Eds.), Textbook of veterinary 496 
internal medicine, eight ed. Saunders, Philadelphia, pp. 1781-1795. 497 
19. Ristic, J.M., Herrtage, M.E., Walti-Lauger, S.M., Slater, L.A., 498 
Church, D.B., Davison, L.J., Catchpole, B., 2005. Evaluation of a 499 
continuous glucose monitoring system in cats with diabetes mellitus. 500 
J Feline Med Surg. 7, 153-162. 501 
20. Rodbard, H.W., Cariou, B., Zinman, B., Handelsman, Y., Philis-502 
Tsimikas, A., Skojth, T.V., Rana, A., Methieu, C., BEGIN Once 503 
Long trial investigators, 2013. Comparison of insulin degludec with 504 
insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-505 
year randomized, treat-to-target trial. Diabet Med. 30, 1298-1304. 506 
21. Siegmund, T., Kolassa, R., Thomas, A., 2011. Sensor-based therapy 507 
and sensor-based pump therapy. Unimed Science, Bremen. 508 
22. Smith, J.R., Vrono, Z., Rappoport, G.S., Turek, M.M., Creevy, K.E., 509 
2012. A survey of southeastern United States veterinarians` 510 
preferences for managing cats with diabetes mellitus. J Feline Med 511 
Surg. 14(10), 716-722. 512 
23. Surman, S., Fleeman, L., 2013. Continuous glucose monitoring in 513 
small animals. Vet Clin North Am Small Anim Pract. 43, 381-406. 514 
24. Ward, C., Louviere, A., 2015. Efficacy of ProZinc insulin in naive 515 
and insulin-established cats using continuous interstitial glucose 516 
monitoring. 2015 ACVIM Forum Research Abstract Program. J Vet 517 
Intern Med. 29(4), 1171-1172. 518 
27 
 
25. Zini, E., Moretti, S., Tschuor, F., Reusch, C.E., 2009. Evaluation of 519 
a new portable glucose meter designed for the use in cats. Schweiz 520 
Arch Tierheilkd. 151, 448-451. 521 
26. Zinman, B., Fulcher, G., Rao, P.V., Thomas, N., Endahl, L.A., 522 
Johansen, T., Lindh, R., Lewin, A., Rosenstock, J., Pinget, M., 523 
Mathieu, C., 2011. Insulin degludec, an ultra-long-acting basal 524 
insulin, once a day or three times a week versus insulin glargine 525 
once a day in patients with type 2 diabetes: a 16-week, randomised, 526 
open-label, phase 2 trial. Lancet. 377, 924-931. 527 
